Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis
Open Access
- 13 March 2015
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatology
- Vol. 67 (6) , 1577-1585
Abstract
Objective: To examine the epidemiology of serious infections, a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE), in a nationwide cohort of SLE and lupus nephritis (LN) patients.Methods: Using the Medicaid Analytic eXtract database for the years 2000–2006, we identified patients ages 18–64 years who had SLE and the subset who had LN. We ascertained cases of serious hospitalized infections using validated algorithms, and we determined 30‐day mortality rates. Poisson regression was used to calculate infection incidence rates and multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) for the first infection, adjusted for sociodemographic variables, medication use, and an SLE‐specific risk adjustment index.Results: We identified 33,565 patients with SLE, 7,113 of whom had LN. There were 9,078 serious infections in 5,078 SLE patients and 3,494 infections in 1,825 LN patients. The infection incidence rate per 100 person‐years was 10.8 in the SLE cohort and 23.9 in the LN subcohort. In adjusted models for the SLE cohort, we observed increased risks of infection in men as compared to women (HR 1.33 [95% confidence interval (95% CI) 1.20–1.47]), in blacks as compared to whites (HR 1.14 [95% CI 1.06–1.21]), and in users of glucocorticoids (HR 1.51 [95% CI 1.43–1.61]) and immunosuppressive drugs (HR 1.11 [95% CI 1.03–1.20]) as compared to never users. Hydroxychloroquine users had a reduced risk of infection as compared to never users (HR 0.73 [95% CI 0.68–0.77]). The 30‐day mortality rate per 1,000 person‐years among those hospitalized with infections was 21.4 in the SLE cohort and 38.6 in the LN subcohort.Conclusion: In this diverse, nationwide cohort of SLE patients, we observed a substantial burden of serious infections with many subsequent deaths, particularly among those with LN.Keywords
Funding Information
- Lupus Foundation of America (Career Development Award)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR057327)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24066109)
This publication has 43 references indexed in Scilit:
- Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004Arthritis & Rheumatism, 2012
- Differences between Male and Female Systemic Lupus Erythematosus in a Multiethnic PopulationThe Journal of Rheumatology, 2012
- Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006Arthritis & Rheumatism, 2011
- Identification and validation of lupus nephritis cases using administrative dataLupus, 2010
- Viruses and lupus: the viral hypothesisLupus, 2008
- Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature reviewRheumatology, 2006
- Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2001
- Time-Dependent Hazard Ratio: Modeling and Hypothesis Testing with Application in Lupus NephritisJournal of the American Statistical Association, 1996
- Predicting Infection in Hospitalized Patients with Systemic Lupus Erythematosus.Internal Medicine, 1996